Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

l Research Institute (DCRI) at Duke University Medical Center and Chair of the Steering Committee for the study.  "For the first time, we've shown that active control of anticoagulation is possible; the hypothesis that this may lead to better ischemic and bleeding outcomes will no doubt be a focus of the REG1 Phase 3 development program."

"Developing a technology that can selectively control anticoagulation has been considered the 'holy grail' for cardiac intervention," said Roxana Mehran, MD, Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Mount Sinai School of Medicine.  "For years, it's been the goal of cardiologists and surgeons to discover a more targeted method of controlling anticoagulation for patients undergoing ACS procedures, and the Phase 2b RADAR results exhibit significant promise toward this objective."

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to person
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
(Date:12/24/2014)... December 24, 2014 ... Global Disposable Syringe Industry of 178 pages ... business intelligence library. The 2014 ... Industry is a professional and deep research ... overview analysis, the report introduces Disposable Syringe ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... , BOSTON, Oct. 2 Massachusetts General Hospital (MGH) Cancer ... including three Elekta Infinity and one ... management software , will enable the facility to offer ... The three Infinity systems position MGH ...
... Oct. 2 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... of the previously announced settlement of the legal ... closed an Asset Purchase Agreement ("APA") transaction with ... from Forest,s Inwood line of business. The ANDA ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation 2
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... iFitDress.com, the popular online supplier of wedding dresses and special ... black one-shoulder cocktail dresses . In addition, all these ... discounted prices, up to 70% off. , The ... only. You know, we have thousands of frequent callers in ... items can visit our website for more details. The current ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
(Date:12/25/2014)... News) -- Overeating is common during the holidays, but there ... expert says. "Don,t arrive at a party hungry. It ... you,ll be attending a party, but deprivation leads to hunger, ... Northern Westchester Hospital in Mount Kisco, N.Y., said in a ... the day and even to have a snack before attending ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... publisher of open access journals, is pleased to ... (JCMR) is moving to BioMed Centrals open access ... & Francis. The move from a subscription publisher ... Cardiovascular Magnetic Resonance (SCMR) members and JCMR authors ...
... OCALA, Fla., Dec. 12 Franck,s Compounding Lab ... Pharmacy Services in,Woodruff, Wisconsin. Island Pharmacy owners, Randy ... other personal interests. Selling their,pharmacy to Franck,s Compounding ... ensure the continuance of high quality prescriptions and ...
... and Babies "R" Us to help prepare local moms for the ... ... Dec. 12 With a traditional theme of,pink and blue, local ... Blue Shield hosts a community-wide baby shower today,for local moms-to-be at ...
... found fat mice had harder time fighting gum disease ... people find it harder to fight infections, and a ... new study from Boston University researchers. , In experiments ... , obese mice had less ability to battle gum ...
... antibody,engineering company developing novel antibodies and antibody fragments,based ... that it,has established a Scientific Advisory Board and ... of this advisory body. Members,of f-star,s Scientific Advisory ... College, London, UK, Sir Ravinder Maini is ...
... to six community organizations in ... underserved areas, WOODLAND HILLS, ... a total of $30,000 in end of,year donations to various food banks ... agencies in northern and,southern California to assist vulnerable populations., Blue Cross ...
Cached Medicine News:Health News:Society of Cardiovascular Magnetic Resonance chooses open access 2Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 2Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 3Health News:Obesity Weakens Immune Response 2Health News:Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board 2Health News:Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board 3Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2
For use with Slitlamps which have a smaller distance between the eye and the reduction prism than the Haag-Streit 900. Designed to work with argon/YAG Lasers....
... complete image capture and management application that ... leading ophthalmic clinicians, ophthalmic photographers and optometrists ... securely document the eye via the slit ... slit lamps equipped with digital or video ...
... EyeCap SL is the most advanced means ... capture and management system that acquires extremely ... latest technology.Images can be captured directly from ... cameras, as well as any other ophthalmic ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For children up to 4 years of age. 11 mm internal diameter of t...
Medicine Products: